ANIX Anixa Biosciences Inc
Price (delayed)
$2.73
Market cap
$87.9M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.39
Enterprise value
$87.07M
Anixa Biosciences Inc. is a biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type
Highlights
The company's quick ratio fell by 41% YoY but it rose by 7% QoQ
The gross profit has dropped by 100% year-on-year
The company's revenue has shrunk by 100% YoY
Key stats
What are the main financial stats of ANIX
Market
Valuations
Earnings
Shares outstanding
32.2M
Market cap
$87.9M
Enterprise value
$87.07M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.92
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$13.61M
Net income
-$12.48M
EBIT
-$12.48M
EBITDA
-$12.45M
Free cash flow
-$7.93M
Per share
Balance sheet
Liquidity
EPS
-$0.39
EPS diluted
-$0.39
Free cash flow per share
-$0.25
Book value per share
$0.55
Revenue per share
$0
TBVPS
$0.59
Total assets
$18.91M
Total liabilities
$2.19M
Debt
$230,000
Equity
$17.85M
Working capital
$16.69M
Debt to equity
0.01
Current ratio
9.35
Quick ratio
8.63
Net debt/EBITDA
0.07
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-56.9%
Return on equity
-60%
Return on invested capital
-65.8%
Return on capital employed
-73.8%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ANIX stock price
How has the Anixa Biosciences stock price performed over time
Intraday
-4.55%
1 week
-13.33%
1 month
-13.33%
1 year
-18.51%
YTD
17.67%
QTD
-4.55%
Financial performance
How have Anixa Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$13.61M
Net income
-$12.48M
Gross margin
N/A
Net margin
N/A
The gross profit has dropped by 100% year-on-year
The company's revenue has shrunk by 100% YoY
The net income has declined by 16% year-on-year
ANIX's operating income is down by 13% year-on-year
Growth
What is Anixa Biosciences's growth rate over time
Valuation
What is Anixa Biosciences stock price valuation
P/E
N/A
P/B
4.92
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
ANIX's EPS is down by 15% year-on-year
The equity has contracted by 27% YoY and by 11% from the previous quarter
The price to book (P/B) is 5% higher than the 5-year quarterly average of 4.9 and 5% higher than the last 4 quarters average of 4.9
The company's revenue has shrunk by 100% YoY
Efficiency
How efficient is Anixa Biosciences business performance
The return on equity has declined by 42% year-on-year and by 8% since the previous quarter
The company's return on assets fell by 39% YoY and by 7% QoQ
Anixa Biosciences's return on invested capital has decreased by 35% YoY and by 8% QoQ
Dividends
What is ANIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ANIX.
Financial health
How did Anixa Biosciences financials performed over time
The company's quick ratio fell by 41% YoY but it rose by 7% QoQ
The current ratio has declined by 38% year-on-year but it rose by 9% since the previous quarter
The debt is 99% less than the equity
The debt has increased by 42% YoY
The equity has contracted by 27% YoY and by 11% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.